Literature DB >> 874947

An inactivated rift valley fever vaccine.

B J Barnard, M J Botha.   

Abstract

The immunising potency of an inactivated Rift Valley fever (RVF) vaccine prepared from RVF virus infected mouse brain and RVF infected cell culture was studied in cattle and sheep. Different doses and adjuvants were compared. In laboratory trials both cattle and sheep developed neutralising antibodies against virulent RVF virus and in cattle antibodies were still detectable 9 months after immunisation. Although the immunity produced was inadequate to prevent viraemia after challenge, evidence of protection against clinical RVF was obtained. Field trials in sheep showed that vaccination induced a good immunity in pregnant ewes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 874947

Source DB:  PubMed          Journal:  J S Afr Vet Assoc        ISSN: 1019-9128            Impact factor:   1.474


  24 in total

Review 1.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

Review 2.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

3.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

4.  Detection of human immunoglobulins G and M antibodies to Rift Valley fever virus by enzyme-linked immunosorbent assay.

Authors:  B Niklasson; C J Peters; M Grandien; O Wood
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

5.  Rift Valley Fever - assessment of effectiveness of surveillance and control measures in the EU.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Klaus Depner; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar Schmidt; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Paolo Pasquali; Helen Clare Roberts; Liisa Helena Sihvonen; Karl Stahl; Antonio Velarde Calvo; Arvo Viltrop; Christoph Winckler; Simon Gubbins; Sotiria-Eleni Antoniou; Alessandro Broglia; Josè Cortiñas Abrahantes; Sofie Dhollander; Yves Van der Stede
Journal:  EFSA J       Date:  2020-11-05

6.  Weather, host and vector--their interplay in the spread of insect-borne animal virus diseases.

Authors:  R F Sellers
Journal:  J Hyg (Lond)       Date:  1980-08

Review 7.  Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.

Authors:  Michele Bouloy; Ramon Flick
Journal:  Antiviral Res       Date:  2009-08-12       Impact factor: 5.970

8.  Detection of Rift Valley fever virus antigen by enzyme-linked immunosorbent assay.

Authors:  B Niklasson; M Grandien; C J Peters; T P Gargan
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

9.  Exploratory space-time analyses of Rift Valley Fever in South Africa in 2008-2011.

Authors:  Raphaëlle Métras; Thibaud Porphyre; Dirk U Pfeiffer; Alan Kemp; Peter N Thompson; Lisa M Collins; Richard G White
Journal:  PLoS Negl Trop Dis       Date:  2012-08-28

10.  A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection.

Authors:  Elena López-Gil; Gema Lorenzo; Esther Hevia; Belén Borrego; Martin Eiden; Martin Groschup; Sarah C Gilbert; Alejandro Brun
Journal:  PLoS Negl Trop Dis       Date:  2013-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.